Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma
Authors:
- Amany SalamaASAmany Salama
- Mohammad ArafaMAMohammad Arafa
- Abdelhadi Mohamed SheblASAbdelhadi Mohamed Shebl
- Sylvia A. AshamallahSASylvia A. Ashamallah
- Reda HemidaRHReda Hemida
- Anas GamalAGAnas Gamal
- Abd AlRahman FodaAFAbd AlRahman Foda
- Khaled ZalataKZKhaled Zalata
- El-Said M. Abdel-HadyEAEl-Said M. Abdel-Hady
Open Access
- 15 May 2019
- journal article
- research article
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 53 (3) , 164-172
Abstract
In order to improve the efficacy of endometrial carcinoma (EC) treatment, identifying prognostic factors for high risk patients is a high research priority. This study aimed to assess the relationships among the expression of estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, and the different histopathological prognostic parameters in EC and to assess the value of these in the management of EC. We examined 109 cases of EC. Immunohistochemistry for ER, PR, HER2, and Ki-67 were evaluated in relation to age, tumor size, International Federation of Gynecology and Obstetrics (FIGO) stage and grade, depth of infiltration, cervical and ovarian involvement, lymphovascular space invasion (LVSI), and lymph node (LN) metastasis. The mean age of patients in this study was 59.8 ± 8.2 years. Low ER and PR expression scores and high Ki-67 expression showed highly significant associations with non-endometrioid histology (p = .007, p < .001, and p < .001, respectively) and poor differentiation (p = .007, p < .001, and p <. 001, respectively). Low PR score showed a significant association with advanced stage (p = .009). Low ER score was highly associated with LVSI (p = .006), and low PR scores were associated significantly with LN metastasis (p = .026). HER2 expression was significantly related to advanced stages (p = .04), increased depth of infiltration (p = .02), LVSI (p = .017), ovarian involvement (p = .038), and LN metastasis (p = .038). There was a close relationship between HER2 expression and uterine cervical involvement (p = .009). Higher Ki-67 values were associated with LN involvement (p = .012). The over-expression of HER2 and Ki-67 and low expression of ER and PR indicate a more malignant EC behavior. An immunohistochemical panel for the identification of high risk tumors can contribute significantly to prognostic assessments.Keywords
Funding Information
- Mansoura University
This publication has 39 references indexed in Scilit:
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Current concepts in the pathology and epigenetics of endometrial carcinomaPathology, 2010
- Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical studyVirchows Archiv, 2010
- Selected Immunohistochemical Prognostic Factors in Endometrial CancerInternational Journal of Gynecological Cancer, 2010
- The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomasDiagnostic Pathology, 2010
- GATA3 expression in estrogen receptor α-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survivalAmerican Journal of Obstetrics and Gynecology, 2008
- Increased expression of hypoxia-inducible factor 1α in type I and type II endometrial carcinomasLaboratory Investigation, 2007
- Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancerGynecologic Oncology, 2005
- Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expressionOncogene, 2001
- MIB-1 in Endometrial Carcinoma: Prognostic Significance with 5-Year Follow-UpGynecologic Oncology, 1999